It’s the era of biobanking! Congrats to Cellino!!!

A4LI is proud to be a Community Partner for @foresightinst’s Vision Weekend USA 2026, taking place November 13–15 in San Francisco. Since 1992, Vision Weekend has brought together researchers, builders, and funders working at the forefront of science and technology. This year’s program explores longevity biotech, brain-computer interfaces, AI resilience, and more. Advances in aging science have the potential to transform human health, but translating scientific progress into real-world impact also requires thoughtful policy. Connecting the people driving innovation with those working to advance it is an important part of that process. We look forward to joining the conversation and connecting with others working to extend healthy human lifespan. Learn more and get your tickets: foresight.org/events/vision-…

Diseases like Alzheimer's, Parkinson's, and ALS can develop over many years, with protein misfolding and clumping contributing to damage in the brain and nervous system. By the time symptoms appear, significant damage may already have occurred. Understanding how these changes begin could open new opportunities to detect and treat disease earlier. @ARPA_H's new BIOGAMI program is tackling this challenge, investing up to $152 million over four years to understand how proteins become dysfunctional and develop ways to intervene. Six research teams, including those at the Buck Institute for Research on Aging, Johns Hopkins, MIT, and UC Berkeley, will combine protein science and computational tools to develop new approaches to early detection and treatment. While the initial focus is neurodegenerative disease, the findings could eventually have applications in cancer, diabetes, and other conditions. 📖 Read more here: arpa-h.gov/news-and-events/a… At A4LI, we're encouraged to see ARPA-H invest in understanding the underlying biology of disease. The earlier we can identify and address the processes that contribute to age-related conditions, the more opportunities researchers may have to change how these diseases are treated. We'll continue following BIOGAMI's progress and highlighting the work underway at ARPA-H to advance biomedical innovation.